SCHEMBL4635870

SCHEMBL4635870

CCCOC(=O)c1cccc(O)c1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC28A3 Q9HAS3 4/20 0.56
SLC5A1 P13866 2/20 0.48
HIF1A Q16665 1/20 0.47
EPHX2 P34913 2/20 0.46
SLC5A2 P31639 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TYR P14679 1/20 0.44
ACHE P22303 1/20 0.44
CA12 O43570 1/20 0.44
CA2 P00918 1/20 0.44
P4HB P07237 1/20 0.44
AKR1B1 P15121 1/20 0.44
CA4 P22748 1/20 0.44
CA7 P43166 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4636160 0.91 SLC28A3 (0.58) SLC28A3SLC5A1HIF1AEPHX2SLC5A2
SCHEMBL4636191 0.87 SLC28A3 (0.61) SLC28A3SLC5A1HIF1AEPHX2SLC5A2
SCHEMBL940123 0.86 SLC28A3 (0.57) SLC28A3SLC5A1HIF1ASLC5A2TYR
SCHEMBL942070 0.85 SLC28A3 (0.71) SLC28A3SLC5A1HIF1AEPHX2SLC5A2
SCHEMBL4635629 0.84 SLC28A3 (0.57) SLC28A3SLC5A1HIF1AEPHX2SLC5A2
SCHEMBL4635305 0.83 SLC28A3 (0.61) SLC28A3SLC5A1HIF1AEPHX2SLC5A2
SCHEMBL941363 0.81 NPC1 (0.55) SLC28A3TYRCA12CA2AKR1B1
SCHEMBL941333 0.81 NPC1 (0.63) SLC28A3SLC5A1TYRAKR1B1
SCHEMBL30803032 0.80 SLC28A3 (0.53) SLC28A3SLC5A1HIF1AEPHX2SLC5A2
SCHEMBL4636214 0.80 SLC28A3 (0.56) SLC28A3SLC5A1EPHX2SLC5A2TYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1932514-B1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR EZAKI GLICO CO (JP) 2018-11-14 EP disclosed
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE EZAKI GLICO CO., LTD. (JP) 2014-01-23 US disclosed
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide EZAKI GLICO CO., LTD. (JP) 2008-11-06 US disclosed
EP-1932514-A1 PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR Ezaki Glico Co., Ltd. (JP) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140023602-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE SI, CUTA, CD44 SLC28A3 1164/4885SLC5A1 723/4885HIF1A 634/4885
US-20080274068-A1 External Preparation for Skin Containing a Phosphorlated Saccharide CUTA, SI, CD44 SLC28A3 977/4885SLC5A1 589/4885HIF1A 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.